ArticleBMJ open2020

Pharmacodynamics effects of CDK4/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer: a study protocol for a randomised controlled phase II trial (LEEP study: LEE011 in high-risk, localised Prostate cancer).

Tahlia Scheinberg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.